

CITIC Securities (Hong Kong) Limited

18/F, One Pacific Place

88 Queensway

Hong Kong

The Board of Directors

Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

Room 409, Building H

Self-numbered Creative Building

No. 2 Tengfei Second Street

China-Singapore Guangzhou Knowledge City

Huangpu District, Guangzhou

Guangdong Province, PRC

August 7, 2025

Dear Sir/Madam,

Re: Guangzhou Innogen Pharmaceutical Group Co., Ltd. (廣州銀諾醫藥集團股份有限公司) (the “Company”) – Global Offering and Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)

We, CITIC Securities (Hong Kong) Limited, as a joint sponsor in respect of the proposed global offering (the “**Global Offering**”) and listing of the H shares of the Company on the Main Board of the Stock Exchange, refer to the prospectus of the Company dated August 7, 2025 (the “**Prospectus**”) in connection with the Global Offering.


We hereby give, and confirm that we have not withdrawn, our written consent to (i) the issue of the Prospectus by the Company, with the inclusion therein of all references to our name and qualifications, and the opinions given by us, in the form and context in which they respectively appear in the Prospectus, and (ii) a statement of the aforesaid in the Prospectus, in the form and context in which it appears in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also consent to a copy of this letter and the report being made available on display as described in Appendix VII to the Prospectus.

Unless otherwise stated, capitalized terms used in this letter shall have the same meaning as terms defined in the Prospectus.

For and on behalf of

CITIC Securities (Hong Kong) Limited

A handwritten signature in dark ink, appearing to be 'Peter Ng', is written above a horizontal line.

Name: Peter Ng

Title: Executive Director

China International Capital Corporation Hong Kong Securities Limited

29th Floor, One International Finance Centre

1 Harbour View Street

Hong Kong

The Board of Directors

Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

Room 409, Building H

Self-numbered Creative Building

No. 2 Tengfei Second Street

China-Singapore Guangzhou Knowledge City

Huangpu District, Guangzhou

Guangdong Province, PRC

August 7, 2025

Dear Sir/Madam,

Re: Guangzhou Innogen Pharmaceutical Group Co., Ltd. (廣州銀諾醫藥集團股份有限公司) (the “Company”) – Global Offering and Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)

We, China International Capital Corporation Hong Kong Securities Limited, as a joint sponsor in respect of the proposed global offering (the “**Global Offering**”) and listing of the H shares of the Company on the Main Board of the Stock Exchange, refer to the prospectus of the Company dated August 7, 2025 (the “**Prospectus**”) in connection with the Global Offering.

We hereby give, and confirm that we have not withdrawn, our written consent to (i) the issue of the Prospectus by the Company, with the inclusion therein of all references to our name and qualifications, and the opinions given by us, in the form and context in which they respectively appear in the Prospectus, and (ii) a statement of the aforesaid in the Prospectus, in the form and context in which it appears in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also consent to a copy of this letter and the report being made available on display as described in Appendix VII to the Prospectus.

Unless otherwise stated, capitalized terms used in this letter shall have the same meaning as terms defined in the Prospectus.

For and on behalf of

China International Capital Corporation Hong Kong Securities Limited



Name: Jin Liang
Title: Managing Director



Ernst & Young
27/F, One Taikoo Place
979 King's Road
Quarry Bay, Hong Kong

安永會計師事務所
香港鰂魚涌英皇道 979 號
太古坊一座 27 樓

Tel 電話: +852 2846 9888
Fax 傳真: +852 2868 4432
ey.com

7 August 2025

The Directors

Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

Room 409, Building H, Self-numbered Creative Building

No. 2 Tengfei Second Street

China-Singapore Guangzhou Knowledge City

Huangpu District, Guangzhou

Guangdong Province, China

Dear Sirs,

**Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the "Company") and its subsidiaries
(the "Group")**


Listing on the Main Board of The Stock Exchange of Hong Kong Limited

We refer to the prospectus dated 7 August 2025 (the "Prospectus") in connection with the proposed initial listing of shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited, a copy of which is attached and initialed by us on its front cover for the purpose of identification.

We hereby consent to the inclusion of our accountants' report dated 7 August on the historical financial information for the years ended 31 December 2023 and 2024 and the five months ended 31 May 2025 and our accountants' report dated 7 August 2025 on the pro forma financial information as at 31 May 2025 in the Prospectus, and the references to our name in the form and context in which they are included.

This letter is solely being issued in connection with the filing of the Prospectus regarding the listing of the Company's securities on The Stock Exchange of Hong Kong Limited and not for any other purpose.

Yours faithfully,



Certified Public Accountants

Hong Kong

通商律師事務所

COMMERCE & FINANCE LAW OFFICES

中国上海市南京西路 1515 号静安嘉里中心一座 10 层 200040

10/F, Tower 1, Jing An Kerry Centre, 1515 West Nanjing Road, Shanghai 200040, China

电话 Tel: +86 21 6019 2600 传真 Fax: +86 21 6019 3278

电邮 Email: shanghai@tongshang.com 网址 Web: www.tongshang.com

The Board of Directors

Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

Room 409, Building H

Self-numbered Creative Building

No. 2 Tengfei Second Street

China-Singapore Guangzhou Knowledge City

Huangpu District, Guangzhou

Guangdong Province, PRC

August 7, 2025

Dear Sir/Madam,

Re: Guangzhou Innogen Pharmaceutical Group Co., Ltd. (廣州銀諾醫藥集團股份有限公司) (the “Company”) – Global Offering and Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)

We, Commerce & Finance Law Offices, as the Company’s legal adviser as to the laws of the People’s Republic of China in respect of the proposed global offering (the “**Global Offering**”) and listing of the H shares of the Company on the Main Board of the Stock Exchange, refer to the prospectus of the Company dated August 7, 2025 (the “**Prospectus**”) in connection with the Global Offering.

We hereby give, and confirm that we have not withdrawn, our written consent to (i) the issue of the Prospectus by the Company, with the inclusion therein of all references to our name and qualifications, and the opinions given by us, in the form and context in which they respectively appear in the Prospectus, and (ii) a statement of the aforesaid in the Prospectus, in the form and context in which it appears in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also consent to a copy of this letter and the opinions being made available on display as described in Appendix VII to the Prospectus.

Unless otherwise stated, capitalized terms used in this letter shall have the same meaning as terms defined in the Prospectus.

Yours faithfully

For and on behalf of

Commerce & Finance Law Offices

Chen Ken

Name: Chen Ken(陈垦)

Title: Partner

The Board of Directors

Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

Room 409, Building H
Self-numbered Creative Building
No. 2 Tengfei Second Street
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangzhou
Guangdong Province, PRC

August 7, 2025

Dear Sir/Madam,

Re: Guangzhou Innogen Pharmaceutical Group Co., Ltd. (廣州銀諾醫藥集團股份有限公司) (the “Company”) – Global Offering and Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)

We, Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., as the industry consultant in respect of the proposed global offering (the “Global Offering”) and listing of the H shares of the Company on the Main Board of the Stock Exchange, refer to the prospectus of the Company dated August 7, 2025 (the “Prospectus”) in connection with the Global Offering.

We hereby give, and confirm that we have not withdrawn, our written consent to (i) the issue of the Prospectus by the Company, with the inclusion therein of all references to our name and qualifications, and the opinions given by us, in the form and context in which they respectively appear in the Prospectus, and (ii) a statement of the aforesaid in the Prospectus, in the form and context in which it appears in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus and referring to it in the Prospectus. We also consent to a copy of this letter and the report being made available on display as described in Appendix VII to the Prospectus.

Unless otherwise stated, capitalized terms used in this letter shall have the same meaning as terms defined in the Prospectus.

Yours faithfully

For and on behalf of

Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.



Name: Yves Wang

Title: Managing Partner & President